Neurological features and outcome in COVID-19: dementia can predict severe disease

Ghaffari, Mostafa; Ansari, Hossein; Moghadam, Nahid Beladi; Aghamiri, Seyed Hossein; Haghighi, Mehrdad; Nabavi, Mahmoud; Mansouri, Behnam; Mehrpour, Masoud; Assarzadegan, Farhad; Hesami, Omid; Sedaghat, Meghdad; Farahbakhsh, Mohammad; Lima, Behnam Safarpour

doi:10.1007/s13365-020-00918-0

Cited by 26 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the reasons underlying this association have not been identified, 2 persistent chronic inflammation in diabetes combined with poor control of blood glucose levels during the COVID-19 illness and combined comorbidities of diabetes in itself can affect the prognosis of COVID-19 in patients with diabetes. 33 Some studies showed that patients with dementia, especially those living in care facilities, had an increased risk of COVID-19 and COVID-19-related mortality, 34 35 36 consistent with our findings. Living in care facilities favors the rapid spread of COVID-19 due to the increased likelihood of exposure to the virus in a closed environment, and furthermore, patients with dementia tend to have other underlying comorbidities.…”

Section: Discussionsupporting

confidence: 89%

Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram

et al. 2021

View full text Add to dashboard Cite

Background Prediction of mortality in patients with coronavirus disease 2019 (COVID-19) is a key to improving the clinical outcomes, considering that the COVID-19 pandemic has led to the collapse of healthcare systems in many regions worldwide. This study aimed to identify the factors associated with COVID-19 mortality and to develop a nomogram for predicting mortality using clinical parameters and underlying diseases. Methods This study was performed in 5,626 patients with confirmed COVID-19 between February 1 and April 30, 2020 in South Korea. A Cox proportional hazards model and logistic regression model were used to construct a nomogram for predicting 30-day and 60-day survival probabilities and overall mortality, respectively in the train set. Calibration and discrimination were performed to validate the nomograms in the test set. Results Age ≥ 70 years, male, presence of fever and dyspnea at the time of COVID-19 diagnosis, and diabetes mellitus, cancer, or dementia as underling diseases were significantly related to 30-day and 60-day survival and mortality in COVID-19 patients. The nomogram showed good calibration for survival probabilities and mortality. In the train set, the areas under the curve (AUCs) for 30-day and 60-day survival was 0.914 and 0.954, respectively; the AUC for mortality of 0.959. In the test set, AUCs for 30-day and 60-day survival was 0.876 and 0.660, respectively, and that for mortality was 0.926. The online calculators can be found at https://koreastat.shinyapps.io/RiskofCOVID19/ . Conclusion The prediction model could accurately predict COVID-19-related mortality; thus, it would be helpful for identifying the risk of mortality and establishing medical policies during the pandemic to improve the clinical outcomes.

show abstract

Section: Discussionsupporting

confidence: 89%

Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In total, 34 studies provided information on the severity of COVID-19 disease. Of them, four studies were preprints (Al Harthi et al 2020 ; Bertlich et al 2020 ; Papizadeh et al 2020 ; Patel et al 2020 ), and 30 articles were published studies (Aggarwal et al 2020 ; Alasia et al 2021 ; Alizadehsani et al 2021 ; Allenbach et al 2020 ; Amanat et al 2021 ; Borobia et al 2020 ; Delorme et al 2021 ; Elimian et al 2020 ; Ermis et al 2021 ; García-Azorín et al 2021 ; Ghaffari et al 2021 ; Goyal et al 2021 ; Izquierdo et al 2020 ; Kadiane-Oussou et al 2020 ; Kocayığıt et al 2021 ; Lechien et al 2021 ; Liotta et al 2020 ; Mao et al 2020 ; McElvaney et al 2020 ; Muñoz-Rodríguez et al 2021 ; Printza et al 2021 ; Romero-Sánchez et al 2020 ; Salepci et al 2021 ; Sobhani et al 2021 2021 ; Song et al 2021 ; Studart-Neto et al 2020 ; Sun et al 2021 ; Tomlins et al 2020 ; Vaira et al 2020 ; Vial et al 2020 ). The OD were present in 482 severely ill and 2640 non-severely ill patients with COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The incidences of at least one new-onset neurological signs/symptoms in the context of COVID-19 infection were extremely wide-ranging, i.e., ~ 12 to ~ 85%. The wide extent of these percentages was based on retrospective and prospective studies from various countries: Austria (Zifko et al 2021); China (Mao et al 2020;Xiong et al 2020) Egypt (Khedr et al 2021); Iran (Amanat et al 2021;Ghaffari et al 2021); Italy (Benussi et al 2020;Rifino et al 2021;Travi et al 2021); France (Kremer et al 2020); Germany (Fleischer et al 2021); Mexico (Flores-Silva et al 2021); Pakistan (Iltaf et al 2020); Poland (Wnuk et al 2021); Portugal (Oliveira et al 2021); South Korea (Kim et al 2021);Spain (García-Azorín et al 2021a, b;García-Moncó et al 2020;García-Azorín et al 2021a, b;Romero-Sánchez et al 2020); Turkey (Karadaş et al 2020;Yuksel et al 2021); United States of America (Chachkhiani et al 2020;Eskandar et al 2021;Frontera et al 2021;Liotta et al 2020); multinational (Chou et al 2021). Systematic reviews with or without meta-analysis (Cagnazzo et al 2021;Chua et al 2020;Collantes et al 2021;Pinzon et al 2020;Romoli et al 2020;Tsai et al 2020;Vakili et al 2021) and narrative/ scoping reviews (Ahmed et al 2020;Maury et al 2021;Roy et al 2021...…”

Section: Discussionmentioning

confidence: 99%

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

Espiritu

Anlacan

et al. 2021

J Neural Transm

View full text Add to dashboard Cite

Our study aimed to determine the effects of new-onset neurological symptoms (NNS) on clinically relevant outcomes in hospitalized patients with COVID-19 infection. We conducted a nationwide, comparative, retrospective, cohort study among adult, hospitalized COVID-19 patients involving 37 hospital sites from various regions in the Philippines. We included a total of 10,881 patients with confirmed COVID-19 infection (2008 had NNS while 8873 did not have NNS). The adjusted hazard ratios (aHRs) for mortality among the mild and severe cases were significantly higher by 1.660 (95% CI 1.132–2.435) and by 1.352 (95% CI 1.042–1.752), respectively, in the NNS group compared to those in the non-NNS group. The aHRs for respiratory failure in the NNS group were significantly increased by 1.914 (95% CI 1.346–2.722), by 1.614 (95% CI 1.260–2.068), and by 1.234 (95% CI 1.089–1.398) among the mild, severe, and critical cases, respectively. The aHRs for ICU admission in the NNS group were still significantly higher by 1.973 (95% CI 1.457–2.673) and by 1.831 (95% CI 1.506–2.226) among the mild and severe cases, respectively. Patients who had NNS were not significantly associated with a longer duration of ventilator dependence (adjusted odds ratio (aOR) 0.954, 95% CI 0.772–1.179), longer ICU stay (aOR 0.983, 95% CI 0.772–1.252) and longer hospital admission (aOR 1.045, 95% CI 0.947–1.153). The presence of NNS significantly increases the risk of mortality, respiratory failure and ICU admission among COVID-19 patients. Registration and associated protocol publication: ClinicalTrials.gov website (NCT04386083); Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. The Philippine COVID-19 Outcomes: a Retrospective study Of Neurological manifestations and Associated symptoms (The Philippine CORONA study): a protocol study. BMJ Open. 2020;10:e040944.

show abstract

Neurological features and outcome in COVID-19: dementia can predict severe disease

Cited by 26 publications

References 33 publications

Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram

Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram

Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis

COVID-19 outcomes of 10,881 patients: retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study)

Contact Info

Product

Resources

About